-
FDA Warning Letter Cites Abraxane Manufacturing Sterility Issues
15 Nov 2022 22:04 GMT
… which manufactures the chemotherapy drug Abraxane (paclitaxel), citing ongoing contamination … cancer, advanced non-small cell lung cancer, and metastatic breast cancer.
Abraxis … remediation, and potential effects on Abraxane supply, a company spokesperson …
-
GNPNAT1 Predicts Poor Prognosis and Cancer Development in Non-Small Cell Lung Cancer
10 Aug 2022 20:52 GMT
… of lung cancers are classified as non-small cell lung cancer (NSCLC … Abraxane resulted in significant downregulation of GNPNAT1 in lung cancer … Metastatic Ability of Lung Cancer Cells
GNPNAT1 mRNA … detected its function in lung cancer cells, and consequently …
-
Lung Cancer Therapies Market Share, Current Trends and Research Development Report to 2025
03 Dec 2020 02:40 GMT
… the cigarette causes lung cancers. As tumors … Lung Cancer, Pressure activated Lung Cancer and Side button Lung Cancer … lung cancer like Abraxane and the growing approvals in the lung cancer … Lung Cancer, Pressure activated Lung Cancer, Side button Lung Cancer, …
-
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb
09 Nov 2020 12:30 GMT
… advanced non-small cell lung cancer (NSCLC) with a … advanced non-small cell lung cancer. With this expansion, … of non-small cell lung cancer and pancreatic cancer. Kitov … lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE …
-
BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
29 May 2020 12:00 GMT
… squamous non-small cell lung cancer (NSCLC), presented at … carboplatin or nab-paclitaxel (ABRAXANE®i) and carboplatin … where lung cancer death rates are decreasing, the lung cancer incidence … squamous non-small cell lung cancer (NSCLC). Currently, 15 …
-
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
20 Apr 2020 20:05 GMT
… or nab-paclitaxel (ABRAXANE®) and carboplatin compared … countries where lung cancer death rates are decreasing, lung cancer incidence … lung cancer comprises the most common form of lung cancer … extensive-stage small cell lung cancer (NCT04005716);
Phase 3 …
-
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
21 Jan 2020 12:00 GMT
… squamous non-small cell lung cancer (NSCLC), met the … bound (nab) paclitaxel (ABRAXANE®) and carboplatin, or paclitaxel … program for tislelizumab in lung cancer, which includes three … countries where lung cancer death rates are decreasing, lung cancer incidence …
-
BeiGene lung cancer treatment improves progression-free survival
21 Jan 2020 13:14 GMT
… therapy combination helped newly diagnosed lung cancer patients live longer by preventing … Bristol-Myers Squibb Co’s Abraxane.
Both combinations of tislelizumab were … for tislelizumab for lung cancer with Chinese health regulators.
Lung cancer is the leading …
-
Roche wins FDA approval for immunotherapy cocktail against lung cancer
04 Dec 2019 06:38 GMT
… treatment for a form of lung cancer as the Swiss drugmaker seeks … Tecentriq mixed with Celgene’s Abraxane and carboplatin chemotherapy to treat … non-squamous non-small cell lung cancer (NSCLC) with no EGFR or …
-
Roche's Tecentriq Combo Gets EU Nod For Difficult Lung Cancer
06 Sep 2019 14:35 GMT
… ’s (NASDAQ:CELG) Abraxane], for the first-line … advanced bladder cancer, advanced lung cancer, and in combination with … has nine Phase III lung cancer studies underway, evaluating Tecentriq … for different types of lung cancer.
Nevertheless, competition is …
About
© 1995-2023